Founded in 2021, Suzhou Industrial Park Ding Xin Pharmaceutical Innovation Research Center (hereafter refer to Ding Xin Research Center) is a social organization engaged in non-profit social service activities.
Guided by Suzhou Industrial Park Technology Innovation Committee, Ding Xin Research Center is focusing on pharmaceutical innovation research, conducting academic exchange to enhance the development of pharmaceutical innovation industry in China. With the core purpose of promoting pharmaceutical innovation and efficiency of transformation of scientific and technological achievements, Ding Xin Research Center is continuously committed to building a highly-efficient communication platform for both academic and industrial fields, to advance basic scientific research and transformation of achievements, accelerate scientific research and strengthen original innovation capacities, to enhance high-quality development of pharmaceutical industry in China.
Major work of Ding Xin Research Center includes: first, to conduct researches on pharmaceutical innovation industry policy and transformation mechanism of basic scientific research and transformation of achievements, providing valuable suggestions for decision-makers in relevant government agencies; second, to hold international influential pharmaceutical conference to strengthen collaborative innovation of government, enterprises, universities, research and capital to broaden cooperation channels; to organize expert/project seminars on hot spots on transformation of pharmaceutical achievements and pain points; third, based on prize selection of pharmaceutical innovation industry, to guide and stimulate original innovation as well as disruptive technological innovation in China, reflecting achievements of pharmaceutical innovation in China and its contribution to the world.
In the future, Ding Xin Research Center will uphold its core purpose, adhere to the leadership of the Communist Party of China, and make continuous efforts to improve the innovative capacities of industries, enhance the accessibility of innovative drugs, and promote the sustainable development of innovative pharmaceutical industries.